Entropy Neurodynamics Limited (ASX: ENP) — Perfil da empresa, notícias e dados financeiros
Entropy Neurodynamics Limited is a clinical-stage biotechnology company focused on developing proprietary drug formulations for psychedelic-assisted therapy.
Entropy Neurodynamics Limited
Entropy Neurodynamics Limited is a clinical-stage biotechnology company focused on developing proprietary drug formulations for psychedelic-assisted therapy. The company specializes in intravenous infusion formulations of psilocin, the active metabolite of psilocybin, designed to provide precise control over dosing depth and treatment duration in clinical settings. Its research pipeline addresses neuropsychiatric and chronic pain disorders, including binge eating disorder, fibromyalgia, and irritable bowel syndrome. By combining targeted administration methods with structured psychotherapy, the firm aims to address unmet medical needs while improving treatment safety, scalability, and patient management workflows.
Resumo
Operações
Produtos e/ou serviços de Entropy Neurodynamics Limited
- Intravenous Psilocin Formulations: Proprietary intravenous infusion delivery systems for psilocin designed to provide rapid onset, precise dose control, and reduced treatment duration for neuropsychiatric and chronic pain disorders in clinical environments.
- Oral Psilocybin Formulations: Synthetic oral psilocybin drug candidates utilized in clinical proof-of-concept trials to evaluate therapeutic efficacy and safety across multiple central nervous system and chronic pain indications.
- Binge Eating Disorder Therapeutics: Clinical-stage drug development programs evaluating psilocin and psilocybin therapies integrated with psychotherapy to address underlying neurological mechanisms and reduce binge episodes in patients with binge eating disorder.
- Fibromyalgia Pain Therapies: Phase 2 clinical trial programs evaluating precision psychedelic dosing in combination with guided psychotherapy to reduce severe chronic pain and improve functional outcomes for patients suffering from fibromyalgia.
- Visceral Pain and IBS Treatments: Clinical-stage research programs targeting chronic abdominal discomfort and visceral hypersensitivity in patients with irritable bowel syndrome through targeted serotonin receptor modulation and structured psychological support.
- Depression and Neuropsychiatric Pipeline: Clinical research initiatives investigating controlled intravenous psilocin administration to treat major depressive disorder and other high-unmet-need neuropsychiatric conditions in real-world clinical workflows.
equipe executiva do Entropy Neurodynamics Limited
- Jason Alan CarrollMD, CEO & Executive Director
- James P. GilliganPresident & Chief Scientific Officer
- Christopher Leo NtoumenopoulosExecutive Director
- Hamish GeorgeCFO & Company Secretary
- Michael H. SilvermanChief Medical Officer
- Meghna PiplaniJoint Company Secretary
Últimas notícias sobre a Entropy Neurodynamics Limited
Entropy Neurodynamics reports positive Phase 2 psilocin trial
AustraliaEntropy Neurodynamics secures approval for 72 patient study
AustraliaEntropy Neurodynamics targets US$1.9B market
AustraliaEntropy Neurodynamics trial reports 74% episode reduction
AustraliaEntropy advances IBS treatment with new US patent
AustraliaEntropy Neurodynamics see psychedelic response in BED trial
Australia
Comunicados recentes
O que a Entropy Neurodynamics Limited (ENP) comunicou ao mercado, do mais recente para o mais antigo.
- TRP-8803 60-Minute Infusion Achieved in Phase 2 BED StudyFato relevante
- 2026 AGM Notice of Meeting, Letter of Access and Proxy
- Notification regarding unquoted securities - ENP
Principais indicadores financeiros
Resultados divulgados pela Entropy Neurodynamics Limited, em AUD.
- Cap. de mercado
- 50,7 mi
- Receita (TTM)
- 1,9 mi
- P/L
- —
- LPA (diluído, TTM)
- 0.0
- Dividend yield
- —
- Margem de lucro
- -255.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| — | -6,8 mi | -4,9 mi | |
| 1,6 mi | -6,7 mi | -5,3 mi | |
| 1,1 mi | -5 mi | -6,1 mi | |
| 618,6 mil | -9,6 mi | -7,1 mi |